Form 8-K - Current report:
SEC Accession No. 0001213900-21-015427
Filing Date
2021-03-15
Accepted
2021-03-15 17:16:27
Documents
2
Period of Report
2021-03-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea137714-8k_relmada.htm 8-K 20604
2 CONCLUSIONS OF PRECLINICAL ABUSE STUDIES ON REL-1017 (ESMETHADONE) ea137714ex99-1_relmada.htm EX-99.1 5589
  Complete submission text file 0001213900-21-015427.txt   27369
Mailing Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022
Business Address 880 3RD AVENUE, 12TH FLOOR NEW YORK NY 10022 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 21742501
SIC: 2834 Pharmaceutical Preparations